Relmada Therapeutics, Inc. Share Price OTC Markets
Equities
RLMD
US75955J4022
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.695 USD | 0.00% |
|
+8.91% | +139.13% |
01/07 | Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell Microcap Growth Index | CI |
01/07 | Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell 3000E Growth Index | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 114M 9.5B |
---|---|---|---|---|---|
Net income 2024 * | -102M -8.52B | Net income 2025 * | -120M -10.02B | EV / Sales 2024 * | - |
Net cash position 2024 * | 159M 13.3B | Net cash position 2025 * | 89.3M 7.46B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.25
x | P/E ratio 2025 * |
-1.46
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.96% |
Latest transcript on Relmada Therapeutics, Inc.
1 day | -66.13% |
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 31/12/31 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 12/15/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 14/15/14 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 12/15/12 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.22% | 126B | |
+22.79% | 118B | |
+23.26% | 27.87B | |
-19.35% | 20.95B | |
-15.13% | 16.92B | |
-14.52% | 16.18B | |
+9.51% | 14.84B | |
-46.10% | 14.79B | |
+50.47% | 14.08B |
- Stock Market
- Equities
- RLMD Stock
- RLMD Stock